癌症幸存者心血管疾病负担与危险因素管理:多族裔社会经济贫困城市人群的匹配队列研究
该匹配队列研究利用127家城市基层诊所电子健康记录,将18 839例癌症幸存者按1:4匹配非癌对照,评估20种癌症幸存者的CVD负担及危险因素控制。结果显示幸存者所有CVD的 odds 均升高且因癌种和族裔而异,尽管血压控制略优,仍有三分之一未达标,他汀使用与胆固醇管理与对照相似但存在族裔差异。
要点
- 癌症幸存者所有CVD的 odds 均升高,心衰在血液和乳腺癌后更高。
- 静脉血栓栓塞风险在卵巢癌幸存者中最高(OR 5.72)。
- 约三分之一癌症幸存者血压未达指南目标,需优化管理。
核心结论
- 癌症幸存者CVD风险升高,且因癌种和族裔不同而异。
- 尽管主要危险因素控制相当或略优,仍有显著比例未达指南推荐目标。
研究设计与样本
- 匹配队列研究,使用127家城市基层诊所电子健康记录。
- 癌症幸存者按1:4匹配非癌对照,共纳入18 839例幸存者(43%男性,平均年龄64±15岁)。
主要发现
- 癌症幸存者所有CVD的 odds 均升高,独立于共享危险因素。
- 心衰在血液肿瘤(OR 2.12;95% CI 1.44 to 3.09)和乳腺癌幸存者(OR 1.38;95% CI 1.16 to 1.64)中更常见。
- 膀胱癌(OR 1.50;95% CI 1.20 to 1.87)和肺癌(OR 1.44;95% CI 1.09 to 1.87)缺血性心脏病 odds 更高。
- 静脉血栓栓塞风险在卵巢癌最高(OR 5.72;95% CI 3.54 to 9.32)。
- 癌症幸存者血压控制略好(OR 0.92;95% CI 0.87 to 0.97),但三分之一未达指南目标。
关键数值与推荐
- 血压控制:癌症幸存者 vs 对照 OR 0.92(95% CI 0.87 to 0.97)。
- 心衰:血液肿瘤 OR 2.12(95% CI 1.44 to 3.09),乳腺癌 OR 1.38(95% CI 1.16 to 1.64)。
- 缺血性心脏病:膀胱癌 OR 1.50(95% CI 1.20 to 1.87),肺癌 OR 1.44(95% CI 1.09 to 1.87)。
- 静脉血栓栓塞:卵巢癌 OR 5.72(95% CI 3.54 to 9.32)。
临床怎么用
- 对癌症幸存者应加强CVD风险评估,尤其关注心衰和静脉血栓栓塞高发癌种。
- 血压管理虽略优但仍有三分之一未达标,需强化达标策略。
- 他汀使用和胆固醇管理总体与对照相似,但需关注特定族裔差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiovascular disease (CVD) burden and risk factor management among cancer survivors, especially in socioeconomically deprived, multiethnic populations, remain understudied. This study examines CVD burden and risk factor control in survivors of 20 cancer types within a diverse urban population. METHODS: This matched cohort study used electronic health records from 127 urban primary care practices. Cancer survivors were matched to non-cancer comparators at a 1:4 ratio. Cancer and CVD diagnoses were defined using standard clinical code sets. Sociodemographic variables, lifestyle behaviours, blood pressure, cholesterol levels and statin prescriptions were analysed. Multivariable regression evaluated associations between cancer history, CVD prevalence and risk factor control. RESULTS: The cohort included 18 839 cancer survivors (43% men, average age 64±15 years), with high ethnic diversity (48% White, 24% Black, 22% Asian) and high deprivation levels. Cancer survivors had elevated odds of all CVDs considered, independent of shared risk factors. Heart failure was more common in haematological (OR 2.12; 95% CI 1.44 to 3.09) and breast cancer survivors (OR 1.38; 95% CI 1.16 to 1.64). Patients with bladder (OR 1.50; 95% CI 1.20 to 1.87) and lung cancer (OR 1.44; 95% CI 1.09 to 1.87) had higher odds of ischaemic heart disease. Venous thromboembolism risk was highest in ovarian cancer (OR 5.72; 95% CI 3.54 to 9.32). Blood pressure control was slightly better in cancer survivors (OR 0.92; 95% CI 0.87 to 0.97), yet one in three patients did not meet guideline-directed targets. Statin use and cholesterol management were similar between survivors and controls, but disparities were observed within certain ethnic groups. CONCLUSION: Cancer survivors have an elevated risk of CVD, with variations by cancer type and ethnicity. Despite comparable or slightly better control of major risk factors, a significant proportion of cancer survivors do not achieve guideline-recommended targets, highlighting the need for optimised management strategies, particularly in high-risk subgroups.
引用
- Szabo L, Cooper J, Condurache DG, et al. Cardiovascular disease burden and risk factor management in cancer survivors: insights into a multiethnic, socioeconomically deprived urban population. Heart. 2025. PMID: 40081937. doi:10.1136/heartjnl-2024-325309
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。